Resmed at ERS 2026: Advancing Sleep Apnea Care Through Research Across the Therapy Journey

Studies examine long-term PAP outcomes, personalized approaches to care and new technologies that could help identify obstructive sleep apnea (OSA) earlier

London, September 1, 2026 - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it will present new research at the European Respiratory Society (ERS) Congress 2026, offering insights into how obstructive sleep apnea (OSA) can be identified and managed, and the factors associated with long-term therapy engagement and health outcomes.

Among the research being presented Sept. 5-9 in Barcelona, Spain, one study found that each additional hour of nightly positive airway pressure (PAP) use was associated with a lower risk of death among people with OSA. Additional studies explore how wearable technology could help identify people at risk for OSA at scale, female-specific approaches to OSA screening, and factors associated with long-term therapy engagement and outcomes.

Resmed researchers and international experts will present 14 studies at the congress, including two late-breaking abstracts.

ERS Research Highlights:

Helping More People Get Diagnosed

• Female-Specific Approaches to Screening Could Improve OSA Detection in Women
  • Abstract Title: Development of a female-specific obstructive sleep apnoea (OSA) screening questionnaire
  • Presented by: Dr. Alison Wimms
  • September 8, 8:00 - 9:30 a.m. CEST
• Late-Breaking Abstract: Wearable Technology Could Help Identify More People at Risk for OSA
  • Abstract Title: Wearable photoplethysmography enables scalable detection of obstructive sleep apnoea in a large population cohort
  • Presented by: Dr. Faizan Javed, PhD
  • September 8, 12:30 - 2:00 p.m. CEST

Understanding What Drives Long-Term Therapy Success

• Connected Health Data Provides New Insight Into Long-Term PAP Use
  • Study Title: Long-Term Real-World Evaluation of PAP Utilisation Patterns and Therapy Effectiveness in a Large European Population Using Connected Health Data
  • Presented by: Holger Woehrle
  • September 6, 2:15 - 3:30 p.m. CEST
• Women Achieved Better PAP Therapy Outcomes Than Men Despite Similar Adherence
  • Study Title: Gender-Specific Patterns in PAP Adherence, Usage and Therapy Outcomes: Insights from a Large Real-World European Cohort
  • Presented by: Prof. Dr. Christoph Schöbel
  • September 7, 12:30 - 2:00 p.m. CEST
• Late-Breaking Abstract: Each Additional Hour of PAP Use Associated With Lower Mortality Risk
  • Abstract Title: Dose-response relationship between continuous positive airway pressure therapy usage and all-cause mortality and major adverse cardiovascular events in obstructive sleep apnoea: a French national database analysis
  • Presented by: Prof. Dr. Jean-Louis Pépin
  • September 8, 3:45 - 5:00 p.m. CEST

Future Cardiovascular Risks Associated With Sleep Disorders

• People With Both Insomnia and Sleep Apnea Could Face Growing Cardiovascular Risks by 2050
  • Abstract Title: Comorbid Insomnia and Obstructive Sleep Apnea (COMISA) and Cardiovascular Disease in Three European Countries: Population Projections Through 2050
  • Presented by: Dr. Alison Wimms
  • September 8, 3:45 - 5:00 p.m. CEST

Skills Labs and Educational Opportunities:

Resmed is also working with clinical experts to translate science into everyday practice through two interactive Skills Labs focused on helping to improve patient experience, engagement and long-term outcomes in PAP therapy and noninvasive ventilation (NIV).

Skills Lab 1: Putting patient experience at the center of CPAP therapy
Sunday, September 6 | 10:45 - 11:30 a.m. CEST

The session will explore the role of mask choice in patient experience, adherence and outcomes, as well as how digital health can help turn patient engagement into sustained treatment adherence.

Chairs: Dr. Elisa Perger and Dr. Justine Frija
Speakers include Dr. Maria Mascareno Ponte, Dr. Agnieszka Matthews and Prof. Chris Carlin

Skills Lab 2: Engaging patients in therapy: the next step in NIV
Monday, September 7 | 10:45 - 11:30 a.m. CEST

The session will explore the role of digital ecosystems in home NIV therapy and practical approaches to supporting patient engagement.

Chairs: Prof. Claudia Crimi and Dr. Maxime Patout
Speakers include Dr. Patrick Murphy and Prof. Carla Ribeiro

Resmed's Connected Care Ecosystem at Booth J.02:

Attendees are also invited to visit Booth J.02 to explore how Resmed's portfolio of masks, connected therapy devices, digital solutions and services can help healthcare professionals support successful therapy initiation, focus attention where it matters and keep patients engaged over time.

For further information on Resmed's presence at ERS, visit www.resmed.co.uk/ers.

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.